Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
ERYTECH Pharma announces the enrollment of the first patient in its Phase II study with ERY-ASP in second line treatment of patients affected by pancreatic cancer.
ERYTECH Pharma announces the enrollment of the first patient in its Phase I/II study with ERY-ASP in Acute Lymphoblastic Leukemia in the United States of America.
ERYTECH Pharma provides a financial update for the second quarter of 2014.
ERYTECH Pharma announces it has appointed Dr Martine George and Mrs Hilde Windels as new independent members to its board of directors.
ERYTECH Pharma participates in 2014 BIO International Convention from June 23 to 26, 2014 in San Diego, CA, USA.
ERYTECH Pharma is attending Le Village des Actionnaires which takes place on June 12, 2014 in Lyon, France.
SCIENTIFIC CONGRESS – ERYTECH Pharma takes part in ASCO 50th Annual Meeting (Amercian Society of Clinical Oncology) which takes place from May 30 to June 3, 2014 in Chicago, Illinois, USA.
FINANCE – Erytech Pharma participates in BIO Equity Europe 2014 which takes place on May 21-22, 2014 in Amsterdam, The Netherlands